Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Biosimilars in the UK: where are we now and where does the NHS want to go?The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges Share XBiosimilars in the UK: where are we now and where does the NHS want to go?https://pharmaphorum.com/views-analysis-market-access/biosimilars-in-the-uk/
From supplier to partner – how industry can work better with the new-look NHSA move towards integrated care systems (ICS), complete with new primary care roles, and a greater focus on Share XFrom supplier to partner – how industry can work better with the new-look NHShttps://pharmaphorum.com/views-analysis-market-access/from-supplier-to-partner-how-industry-can-work-better-with-the-new-look-nhs/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
NICE numbers at 20 – a closer look at cancerThere has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Share XNICE numbers at 20 – a closer look at cancerhttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/
The Japanese healthcare revolutionSomething that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and Share XThe Japanese healthcare revolutionhttps://pharmaphorum.com/views-analysis-oncology/the-japanese-healthcare-revolution/
Who could replace Sir Andrew Dillon at NICE?With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the Share XWho could replace Sir Andrew Dillon at NICE?https://pharmaphorum.com/views-and-analysis/who-could-replace-sir-andrew-dillon-at-nice/
NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
Sharing success to unlock the “triple win” of joint workingThe fortunes of the NHS and the UK’s life sciences industry are intertwined, with each sector’s success or Share XSharing success to unlock the “triple win” of joint workinghttps://pharmaphorum.com/r-d/views-analysis-r-d/sharing-success-to-unlock-the-triple-win-of-joint-working/
